<p>Eledon Pharmaceuticals（纳斯达克代码：ELDN - 获取免费报告）预计将在 2026 年 5 月 13 日星期三市场开盘前发布其 2026 年第一季度的财报。分析师预计 Eledon Pharmaceuticals 本季度每股收益为（$0.22）。鼓励个人访问公司即将发布的 2026 年第一季度财报概览页面，以获取关于定于 2026 年 5 月 12 日星期二东部时间下午 4:00 的电话会议的最新详情。</p>
<p>获取 <strong>Eledon Pharmaceuticals</strong> 的提醒：</p>
<p>Eledon Pharmaceuticals（纳斯达克代码：ELDN - 获取免费报告）上一次发布财报是在 3 月 19 日星期四。该公司报告本季度每股收益（EPS）为（$0.10），超出市场共识预期的（$0.20）$0.10。</p>
<h2>Eledon Pharmaceuticals 股票表现</h2>
<p>纳斯达克 ELDN 周三开盘价为 $3.78。该公司的 50 日移动平均线为 $3.06，200 日移动平均线为 $2.48。Eledon Pharmaceuticals 的 12 个月低点为 $1.35，12 个月高点为 $4.60。该股票的市值为 $2.8672 亿，市盈率为 -7.27，贝塔值为 0.94。</p>
<h2>华尔街分析师预测增长</h2>
<p>另外，Weiss Ratings 在 3 月 27 日星期五的研究报告中重申了对 Eledon Pharmaceuticals 股票的 “卖出（d-）” 评级。三位分析师给予该股票买入评级，一位给予持有评级，一位给予卖出评级。根据 MarketBeat 的数据，该公司的共识评级为 “持有”，共识目标价为 $9.67。</p>
<p><strong>查看我们最新的 ELDN 股票报告</strong></p>
<h2>机构投资者对 Eledon Pharmaceuticals 的看法</h2>
<p>几家机构投资者最近调整了对 ELDN 的持股。法国巴黎银行金融市场在第三季度增持了 Eledon Pharmaceuticals 的股份，增幅为 143.7%。法国巴黎银行金融市场目前拥有该公司 12,154 股股票，价值$31,000，此前在上个季度增持了 7,166 股。Millennium Management LLC 在第四季度购买了 Eledon Pharmaceuticals 的新股份，价值约为$36,000。Virtu Financial LLC 在第四季度购买了 Eledon Pharmaceuticals 的新股份，价值约为$39,000。Cetera Investment Advisers 在第四季度增持了 Eledon Pharmaceuticals 的股份，增幅为 72.9%。Cetera Investment Advisers 目前拥有该公司 26,584 股股票，价值$40,000，此前在上个季度增持了 11,207 股。最后，Marshall Wace LLP 在第四季度购买了 Eledon Pharmaceuticals 的新股份，价值约为$45,000。对冲基金和其他机构投资者持有该公司 56.77% 的股票。</p>
<h2>Eledon Pharmaceuticals 公司简介</h2>
<p>（获取免费报告）</p>
<p>Eledon Pharmaceuticals, Inc 纳斯达克：ELDN 是一家临床阶段的生物制药公司，专注于发现和开发针对平滑肌功能障碍疾病的治疗方案。该公司利用专有的离子通道调节平台，识别和优化小分子化合物，以恢复或抑制平滑肌活动，旨在解决胃肠、肝脏和心血管疾病。</p>
<p>Eledon 的产品管线包括多个针对高未满足需求指征的临床前和早期临床项目。</p>
<h2>特色文章</h2>
<ul>
<li>五只我们更看好的股票，胜过 Eledon Pharmaceuticals</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RUxETg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RUxETg"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在 Eledon Pharmaceuticals 吗？</h2>
<p>在你考虑 Eledon Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Eledon Pharmaceuticals 并不在名单上。</p>
<p>虽然 Eledon Pharmaceuticals 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

ELDN

<p>Eledon Pharmaceuticals (NASDAQ:ELDN) 将于 5 月 13 日公布 2026 年第一季度财报，分析师预测每股亏损 0.22 美元。该公司在 2025 年第四季度报告的每股亏损为 0.10 美元，超出预期。ELDN 股票开盘价为 3.78 美元，市值为 2.8672 亿美元。分析师的评级意见不一，普遍评级为 “持有”，目标价为 9.67 美元。机构投资者持有该股票的 56.77%，公司专注于平滑肌功能障碍的治疗</p>

<p>Eledon Pharmaceuticals (NASDAQ:ELDN - Get Free Report) is expected to be posting its Q1 2026 results before the market opens on Wednesday, May 13th. Analysts expect Eledon Pharmaceuticals to post earnings of ($0.22) per share for the quarter. Individuals are encouraged to explore the company's upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Tuesday, May 12, 2026 at 4:00 PM ET.</p>
<div class="lb-trans"><p>Eledon Pharmaceuticals（纳斯达克代码：ELDN - 获取免费报告）预计将在 2026 年 5 月 13 日星期三市场开盘前发布其 2026 年第一季度的财报。分析师预计 Eledon Pharmaceuticals 本季度每股收益为（$0.22）。鼓励个人访问公司即将发布的 2026 年第一季度财报概览页面，以获取关于定于 2026 年 5 月 12 日星期二东部时间下午 4:00 的电话会议的最新详情。</p>
</div><p>Get <strong>Eledon Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Eledon Pharmaceuticals</strong> 的提醒：</p>
</div><p>Eledon Pharmaceuticals (NASDAQ:ELDN - Get Free Report) last released its earnings results on Thursday, March 19th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.20) by $0.10.</p>
<div class="lb-trans"><p>Eledon Pharmaceuticals（纳斯达克代码：ELDN - 获取免费报告）上一次发布财报是在 3 月 19 日星期四。该公司报告本季度每股收益（EPS）为（$0.10），超出市场共识预期的（$0.20）$0.10。</p>
</div><h2>Eledon Pharmaceuticals Stock Performance</h2>
<div class="lb-trans"><h2>Eledon Pharmaceuticals 股票表现</h2>
</div><p>NASDAQ ELDN opened at $3.78 on Wednesday. The business's 50 day moving average is $3.06 and its two-hundred day moving average is $2.48. Eledon Pharmaceuticals has a 12-month low of $1.35 and a 12-month high of $4.60. The stock has a market capitalization of $286.72 million, a price-to-earnings ratio of -7.27 and a beta of 0.94.</p>
<div class="lb-trans"><p>纳斯达克 ELDN 周三开盘价为 $3.78。该公司的 50 日移动平均线为 $3.06，200 日移动平均线为 $2.48。Eledon Pharmaceuticals 的 12 个月低点为 $1.35，12 个月高点为 $4.60。该股票的市值为 $2.8672 亿，市盈率为 -7.27，贝塔值为 0.94。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>Separately, Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Eledon Pharmaceuticals in a research report on Friday, March 27th. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of &#34;Hold&#34; and a consensus price target of $9.67.</p>
<div class="lb-trans"><p>另外，Weiss Ratings 在 3 月 27 日星期五的研究报告中重申了对 Eledon Pharmaceuticals 股票的 “卖出（d-）” 评级。三位分析师给予该股票买入评级，一位给予持有评级，一位给予卖出评级。根据 MarketBeat 的数据，该公司的共识评级为 “持有”，共识目标价为 $9.67。</p>
</div><p><strong>View Our Latest Stock Report on ELDN</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 ELDN 股票报告</strong></p>
</div><h2>Institutional Investors Weigh In On Eledon Pharmaceuticals</h2>
<div class="lb-trans"><h2>机构投资者对 Eledon Pharmaceuticals 的看法</h2>
</div><p>Several institutional investors have recently modified their holdings of ELDN. BNP Paribas Financial Markets boosted its stake in shares of Eledon Pharmaceuticals by 143.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 12,154 shares of the company's stock worth $31,000 after acquiring an additional 7,166 shares in the last quarter. Millennium Management LLC purchased a new stake in shares of Eledon Pharmaceuticals during the 4th quarter worth approximately $36,000. Virtu Financial LLC purchased a new stake in shares of Eledon Pharmaceuticals during the 4th quarter worth approximately $39,000. Cetera Investment Advisers boosted its stake in shares of Eledon Pharmaceuticals by 72.9% during the 4th quarter. Cetera Investment Advisers now owns 26,584 shares of the company's stock worth $40,000 after acquiring an additional 11,207 shares in the last quarter. Finally, Marshall Wace LLP purchased a new stake in shares of Eledon Pharmaceuticals during the 4th quarter worth approximately $45,000. Hedge funds and other institutional investors own 56.77% of the company's stock.</p>
<div class="lb-trans"><p>几家机构投资者最近调整了对 ELDN 的持股。法国巴黎银行金融市场在第三季度增持了 Eledon Pharmaceuticals 的股份，增幅为 143.7%。法国巴黎银行金融市场目前拥有该公司 12,154 股股票，价值$31,000，此前在上个季度增持了 7,166 股。Millennium Management LLC 在第四季度购买了 Eledon Pharmaceuticals 的新股份，价值约为$36,000。Virtu Financial LLC 在第四季度购买了 Eledon Pharmaceuticals 的新股份，价值约为$39,000。Cetera Investment Advisers 在第四季度增持了 Eledon Pharmaceuticals 的股份，增幅为 72.9%。Cetera Investment Advisers 目前拥有该公司 26,584 股股票，价值$40,000，此前在上个季度增持了 11,207 股。最后，Marshall Wace LLP 在第四季度购买了 Eledon Pharmaceuticals 的新股份，价值约为$45,000。对冲基金和其他机构投资者持有该公司 56.77% 的股票。</p>
</div><h2>Eledon Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Eledon Pharmaceuticals 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Eledon Pharmaceuticals, Inc NASDAQ: ELDN is a clinical-stage biopharmaceutical company focused on the discovery and development of therapies for diseases characterized by smooth muscle dysfunction. The company leverages a proprietary ion-channel modulation platform to identify and optimize small-molecule compounds that can either restore or inhibit smooth muscle activity, with the goal of addressing gastrointestinal, hepatic and cardiovascular disorders.</p>
<div class="lb-trans"><p>Eledon Pharmaceuticals, Inc 纳斯达克：ELDN 是一家临床阶段的生物制药公司，专注于发现和开发针对平滑肌功能障碍疾病的治疗方案。该公司利用专有的离子通道调节平台，识别和优化小分子化合物，以恢复或抑制平滑肌活动，旨在解决胃肠、肝脏和心血管疾病。</p>
</div><p>Eledon’s pipeline comprises several preclinical and early-phase clinical programs targeting high-unmet-need indications.</p>
<div class="lb-trans"><p>Eledon 的产品管线包括多个针对高未满足需求指征的临床前和早期临床项目。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>特色文章</h2>
</div><ul>
<li>Five stocks we like better than Eledon Pharmaceuticals</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Eledon Pharmaceuticals</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RUxETg" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=ELDN"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Eledon Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 Eledon Pharmaceuticals 吗？</h2>
</div><p>Before you consider Eledon Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Eledon Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eledon Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Eledon Pharmaceuticals 并不在名单上。</p>
</div><p>While Eledon Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Eledon Pharmaceuticals 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Eledon Pharmaceuticals (ELDN) 预计将在周三宣布财报